← Back
Data updated: Mar 10, 2026
SUPERNUS PHARMS
NeurologyDermatology
SUPERNUS PHARMS is a specialty pharmaceutical company focused on Neurology, Dermatology. Key products include TROKENDI XR.
2012
Since
5
Drugs
-
Trials
5
Approved (2yr)
Key Drugs
TROKENDI XR
topiramate
AMPA/kainate receptor 5 indications · 2013
GOCOVRI
amantadine hydrochloride
NMDAR 2 indications · 2017
OXTELLAR XR
oxcarbazepine
High-voltage activated calcium channels 1 indications · 2012
QELBREE
viloxazine hydrochloride
Norepinephrine transporter 1 indications · 2021
Recent Activity
GOCOVRI 2025-07-10
Labeling
OSMOLEX ER 2025-07-10
Labeling
TROKENDI XR 2025-03-10
Labeling
QELBREE 2025-01-23
Labeling
OXTELLAR XR 2024-08-14
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 75%
3 drugs
Dermatology 25%
1 drugs
Pipeline Strength Pro
Loading...
Active (4)
Discontinued (1)
Company Info
- First Approval
- 2012-10-19
- Latest
- 2025-07-10
- Applications
- 5